{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T06:17:12Z","timestamp":1770358632991,"version":"3.49.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,3,6]],"date-time":"2023-03-06T00:00:00Z","timestamp":1678060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,3,6]],"date-time":"2023-03-06T00:00:00Z","timestamp":1678060800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Theramex"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1007\/s00198-022-06627-0","type":"journal-article","created":{"date-parts":[[2023,3,6]],"date-time":"2023-03-06T04:11:47Z","timestamp":1678075907000},"page":"977-991","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Fracture risk in women with osteoporosis initiated on gastro-resistant risedronate versus immediate release risedronate or alendronate: a claims data analysis in the USA"],"prefix":"10.1007","volume":"34","author":[{"given":"John A.","family":"Eisman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernard","family":"Cortet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitra","family":"Boolell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raluca","family":"Ionescu-Ittu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francis","family":"Vekeman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie","family":"Heroux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Friederike","family":"Thomasius","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,3,6]]},"reference":[{"key":"6627_CR1","doi-asserted-by":"crossref","unstructured":"Sarafrazi N, Wambogo EA, Shepherd JA (2021) Osteoporosis or low bone mass in older adults: United States, 2017\u20132018. NCHS data brief 1\u20138","DOI":"10.15620\/cdc:103477"},{"key":"6627_CR2","doi-asserted-by":"publisher","unstructured":"Salari N, Ghasemi H, Mohammadi L, et al (2021) The global prevalence of osteoporosis in the world: a comprehensive systematic review and meta-analysis. Journal of Orthopaedic Surgery and Research 16:. https:\/\/doi.org\/10.1186\/s13018-021-02772-0","DOI":"10.1186\/s13018-021-02772-0"},{"key":"6627_CR3","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1007\/s00198-014-2794-2","volume":"25","author":"F Cosman","year":"2014","unstructured":"Cosman F, de Beur SJ, LeBoff MS et al (2014) Clinician\u2019s guide to prevention and treatment of osteoporosis. Osteoporos Int 25:2359\u20132381. https:\/\/doi.org\/10.1007\/s00198-014-2794-2","journal-title":"Osteoporos Int"},{"key":"6627_CR4","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1093\/innovait\/ins123","volume":"92","author":"MP Jeremiah","year":"2015","unstructured":"Jeremiah MP, Unwin BK, Greenawald MH, Casiano VE (2015) Diagnosis and management of osteoporosis. Am Fam Physician 92:261\u2013268. https:\/\/doi.org\/10.1093\/innovait\/ins123","journal-title":"Am Fam Physician"},{"key":"6627_CR5","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1080\/13697137.2021.1951206","volume":"25","author":"M Lorentzon","year":"2022","unstructured":"Lorentzon M, Johansson H, Harvey NC et al (2022) Osteoporosis and fractures in women: the burden of disease. Climacteric 25:4\u201310. https:\/\/doi.org\/10.1080\/13697137.2021.1951206","journal-title":"Climacteric"},{"key":"6627_CR6","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s00198-021-06108-w","volume":"33","author":"F Thomasius","year":"2022","unstructured":"Thomasius F, Palacios S, Alam A et al (2022) Fracture rates and economic outcomes in patients with osteoporosis prescribed risedronate gastro-resistant versus other oral bisphosphonates: a claims data analysis. Osteoporos Int 33:217\u2013228. https:\/\/doi.org\/10.1007\/s00198-021-06108-w","journal-title":"Osteoporos Int"},{"key":"6627_CR7","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1002\/jbmr.2708","volume":"31","author":"RA Adler","year":"2016","unstructured":"Adler RA, El-Hajj Fuleihan G, Bauer DC et al (2016) Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 31:16\u201335. https:\/\/doi.org\/10.1002\/jbmr.2708","journal-title":"J Bone Miner Res"},{"key":"6627_CR8","doi-asserted-by":"publisher","first-page":"395","DOI":"10.2147\/TCRM.S52291","volume":"9","author":"M Pazianas","year":"2013","unstructured":"Pazianas M, Abrahamsen B, Ferrari S, Russell RGG (2013) Eliminating the need for fasting with oral administration of bisphosphonates. Ther Clin Risk Manag 9:395\u2013402. https:\/\/doi.org\/10.2147\/TCRM.S52291","journal-title":"Ther Clin Risk Manag"},{"key":"6627_CR9","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s00198-012-2175-7","volume":"24","author":"MR McClung","year":"2013","unstructured":"McClung MR, Balske A, Burgio DE et al (2013) Treatment of postmenopausal osteoporosis with delayed-release risedronate 35 mg weekly for 2 years. Osteoporos Int 24:301\u2013310. https:\/\/doi.org\/10.1007\/s00198-012-2175-7","journal-title":"Osteoporos Int"},{"key":"6627_CR10","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s00223-018-00512-x","volume":"104","author":"JA Kanis","year":"2019","unstructured":"Kanis JA, Cooper C, Rizzoli R, Reginster JY (2019) Executive summary of the European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Calcif Tissue Int 104:235\u2013238. https:\/\/doi.org\/10.1007\/s00223-018-00512-x","journal-title":"Calcif Tissue Int"},{"key":"6627_CR11","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s00198-011-1791-y","volume":"23","author":"MR McClung","year":"2012","unstructured":"McClung MR, Miller PD, Brown JP et al (2012) Efficacy and safety of a novel delayed-release risedronate 35 mg once-a-week tablet. Osteoporos Int 23:267\u2013276. https:\/\/doi.org\/10.1007\/s00198-011-1791-y","journal-title":"Osteoporos Int"},{"key":"6627_CR12","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1016\/j.clinthera.2019.05.001","volume":"41","author":"P Fardellone","year":"2019","unstructured":"Fardellone P, Lello S, Cano A et al (2019) Real-world adherence and persistence with bisphosphonate therapy in postmenopausal women: a systematic review. Clin Ther 41:1576\u20131588. https:\/\/doi.org\/10.1016\/j.clinthera.2019.05.001","journal-title":"Clin Ther"},{"key":"6627_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/bmjopen-2018-027049","volume":"9","author":"F Fatoye","year":"2019","unstructured":"Fatoye F, Smith P, Gebrye T, Yeowell G (2019) Real-world persistence and adherence with oral bisphosphonates for osteoporosis: a systematic review. BMJ Open 9:1\u201318. https:\/\/doi.org\/10.1136\/bmjopen-2018-027049","journal-title":"BMJ Open"},{"key":"6627_CR14","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.jval.2010.11.010","volume":"14","author":"S Ross","year":"2011","unstructured":"Ross S, Samuels E, Gairy K et al (2011) A meta-analysis of osteoporotic fracture risk with medication nonadherence. Value in Health 14:571\u2013581. https:\/\/doi.org\/10.1016\/j.jval.2010.11.010","journal-title":"Value in Health"},{"key":"6627_CR15","doi-asserted-by":"publisher","first-page":"608","DOI":"10.3109\/13697137.2014.995164","volume":"18","author":"M Vytrisalova","year":"2015","unstructured":"Vytrisalova M, Touskova T, Ladova K et al (2015) Adherence to oral bisphosphonates: 30 more minutes in dosing instructions matter. Climacteric 18:608\u2013616. https:\/\/doi.org\/10.3109\/13697137.2014.995164","journal-title":"Climacteric"},{"key":"6627_CR16","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1007\/s11926-010-0097-y","volume":"12","author":"DJ Becker","year":"2010","unstructured":"Becker DJ, Kilgore ML, Morrisey MA (2010) The societal burden of osteoporosis. Curr Rheumatol Rep 12:186\u2013191. https:\/\/doi.org\/10.1007\/s11926-010-0097-y","journal-title":"Curr Rheumatol Rep"},{"key":"6627_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00223-020-00688-1","volume":"107","author":"SJ Mortensen","year":"2020","unstructured":"Mortensen SJ, Mohamadi A, Wright CL et al (2020) Medications as a risk factor for fragility hip fractures: a systematic review and meta-analysis. Calcif Tissue Int 107:1\u20139. https:\/\/doi.org\/10.1007\/s00223-020-00688-1","journal-title":"Calcif Tissue Int"},{"key":"6627_CR18","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1002\/jbmr.4431","volume":"36","author":"CW Lary","year":"2021","unstructured":"Lary CW, Rosen CJ, Kiel DP (2021) Osteoporosis and dementia: establishing a link. J Bone Miner Res 36:2103\u20132105. https:\/\/doi.org\/10.1002\/jbmr.4431","journal-title":"J Bone Miner Res"},{"key":"6627_CR19","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s00198-018-4732-1","volume":"30","author":"A Balasubramanian","year":"2019","unstructured":"Balasubramanian A, Zhang J, Chen L et al (2019) Risk of subsequent fracture after prior fracture among older women. Osteoporos Int 30:79\u201392. https:\/\/doi.org\/10.1007\/s00198-018-4732-1","journal-title":"Osteoporos Int"},{"key":"6627_CR20","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1002\/jbmr.3116","volume":"32","author":"S Andrich","year":"2017","unstructured":"Andrich S, Haastert B, Neuhaus E et al (2017) Excess mortality after pelvic fractures among older people. J Bone Miner Res 32:1789\u20131801. https:\/\/doi.org\/10.1002\/jbmr.3116","journal-title":"J Bone Miner Res"},{"key":"6627_CR21","first-page":"64","volume":"25","author":"J Glowacki","year":"2005","unstructured":"Glowacki J (2005) (2005) Bisphosphonate and bone. Ortho J Harvard Med School 25:64\u201367","journal-title":"Ortho J Harvard Med School"},{"key":"6627_CR22","first-page":"142","volume":"10","author":"NB Watts","year":"2004","unstructured":"Watts NB, Worley K, Solis AMY et al (2004) Comparison of risedronate to alendronate and calcitonin for early reduction of nonvertebral fracture risk: results from a managed care Administrative Claims Database. J Manag Care Pharm 10:142\u2013151","journal-title":"J Manag Care Pharm"},{"key":"6627_CR23","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1007\/s00198-013-2332-7","volume":"24","author":"R Lindsay","year":"2013","unstructured":"Lindsay R, Watts NB, Lange JL et al (2013) Effectiveness of risedronate and alendronate on nonvertebral fractures: an observational study through 2 years of therapy. Osteoporos Int 24:2345\u20132352","journal-title":"Osteoporos Int"},{"key":"6627_CR24","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1007\/s00198-021-06246-1","volume":"33","author":"J Gleich","year":"2022","unstructured":"Gleich J, Ku\u00dfmaul AC, Steiner E et al (2022) High prevalence of missed information related on bone health in orthogeriatric patients with fragility fractures of the pelvis\u2014an institutional register-based analysis. Osteoporos Int 33:901\u2013907. https:\/\/doi.org\/10.1007\/s00198-021-06246-1","journal-title":"Osteoporos Int"},{"key":"6627_CR25","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1080\/17453674.2021.1878329","volume":"92","author":"N Lundin","year":"2021","unstructured":"Lundin N, Huttunen TT, Enocson A et al (2021) Epidemiology and mortality of pelvic and femur fractures\u2014a nationwide register study of 417,840 fractures in Sweden across 16 years: diverging trends for potentially lethal fractures. Acta Orthop 92:323\u2013328. https:\/\/doi.org\/10.1080\/17453674.2021.1878329","journal-title":"Acta Orthop"},{"key":"6627_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5888\/pcd16.180381","volume":"16","author":"MM Baker-Goering","year":"2019","unstructured":"Baker-Goering MM, Roy K, Howard DH (2019) Relationship between adherence to antihypertensive medication regimen and outof- pocket costs among people aged 35 to 64 with employer-sponsored health insurance. Prev Chronic Dis 16:1\u20136. https:\/\/doi.org\/10.5888\/pcd16.180381","journal-title":"Prev Chronic Dis"},{"key":"6627_CR27","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.semarthrit.2017.12.010","volume":"48","author":"P Heidari","year":"2018","unstructured":"Heidari P, Cross W, Crawford K (2018) Do out-of-pocket costs affect medication adherence in adults with rheumatoid arthritis? A systematic review. Semin Arthritis Rheum 48:12\u201321","journal-title":"Semin Arthritis Rheum"},{"key":"6627_CR28","doi-asserted-by":"publisher","unstructured":"Pawaskar MD, Xu L, Tang Y et al (2018) Effect of medication copayment on adherence and discontinuation in medicare beneficiaries with type 2 diabetes: a retrospective\u00a0administrative claims database analysis. Diabetes Therapy 9:1979\u20131993. https:\/\/doi.org\/10.1007\/s13300-018-0489-y","DOI":"10.1007\/s13300-018-0489-y"},{"key":"6627_CR29","doi-asserted-by":"publisher","unstructured":"Seaman K, Sanfilippo F, Bulsara M, et al (2020) Predictors of ceasing or reducing statin medication following a large increase in the consumer copayment for medications: a retrospective observational study. Public Health Research and Practice 30:. https:\/\/doi.org\/10.17061\/phrp29121905","DOI":"10.17061\/phrp29121905"},{"key":"6627_CR30","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1177\/https","volume":"9","author":"WF Lems","year":"2017","unstructured":"Lems WF, Raterman HG (2017) Critical issues and current challenges in osteoporosis and fracture prevention. An overview of unmet needs. Therapeutic Advances in Musculoskeletal Disease 9:299\u2013316. https:\/\/doi.org\/10.1177\/https","journal-title":"Therapeutic Advances in Musculoskeletal Disease"},{"key":"6627_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/J.BONE.2020.115833","volume":"144","author":"NR Fuggle","year":"2020","unstructured":"Fuggle NR, Curtis B, Clynes M et al (2020) The treatment gap: the missed opportunities for osteoporosis therapy. Bone 144:1\u201319. https:\/\/doi.org\/10.1016\/J.BONE.2020.115833","journal-title":"Bone"},{"key":"6627_CR32","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1002\/jbmr.2565","volume":"30","author":"S Jha","year":"2015","unstructured":"Jha S, Wang Z, Laucis N, Bhattacharyya T (2015) Trends in media reports, oral bisphosphonate prescriptions, and hip fractures 1996\u20132012: an ecological analysis. J Bone Miner Res 30:2179\u20132187. https:\/\/doi.org\/10.1002\/jbmr.2565","journal-title":"J Bone Miner Res"},{"key":"6627_CR33","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1002\/jbmr.2888","volume":"31","author":"S Khosla","year":"2016","unstructured":"Khosla S, Shane E (2016) A crisis in the treatment of osteoporosis. J Bone Miner Res 31:1485\u20131487. https:\/\/doi.org\/10.1002\/jbmr.2888","journal-title":"J Bone Miner Res"},{"key":"6627_CR34","doi-asserted-by":"publisher","unstructured":"Yusuf AA, Cummings SR, Watts NB, et al (2018) Real-world effectiveness of osteoporosis therapies for fracture reduction in post-menopausal women. Archives of Osteoporosis 13:.https:\/\/doi.org\/10.1007\/s11657-018-0439-3","DOI":"10.1007\/s11657-018-0439-3"},{"key":"6627_CR35","doi-asserted-by":"publisher","unstructured":"Reynolds AW, Liu G, Kocis PT, et al (2018) Comparison of osteoporosis pharmacotherapy fracture rates: analysis of a marketScan\u00ae claims database cohort. International Journal of Endocrinology and Metabolism 16:.https:\/\/doi.org\/10.5812\/ijem.12104","DOI":"10.5812\/ijem.12104"},{"key":"6627_CR36","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1185\/03007995.2015.1016606","volume":"31","author":"A Modi","year":"2015","unstructured":"Modi A, Tang J, Sen S, D\u00edez-P\u00e9rez A (2015) Osteoporotic fracture rate among women with at least 1 year of adherence to osteoporosis treatment. Curr Med Res Opin 31:767\u2013777. https:\/\/doi.org\/10.1185\/03007995.2015.1016606","journal-title":"Curr Med Res Opin"},{"key":"6627_CR37","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1007\/s00198-018-4630-6","volume":"29","author":"J Liu","year":"2018","unstructured":"Liu J, Guo H, Rai P et al (2018) Medication persistence and risk of fracture among female Medicare beneficiaries diagnosed with osteoporosis. Osteoporos Int 29:2409\u20132417. https:\/\/doi.org\/10.1007\/s00198-018-4630-6","journal-title":"Osteoporos Int"},{"key":"6627_CR38","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1097\/MLR.0000000000001294","volume":"58","author":"JR Curtis","year":"2020","unstructured":"Curtis JR, Saag KG, Arora T et al (2020) Duration of bisphosphonate drug holidays and associated fracture risk. Med Care 58:419\u2013426. https:\/\/doi.org\/10.1097\/MLR.0000000000001294","journal-title":"Med Care"},{"key":"6627_CR39","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.1007\/s00198-011-1868-7","volume":"23","author":"AS Carmel","year":"2012","unstructured":"Carmel AS, Shieh A, Bang H, Bockman RS (2012) The 25(OH)D level needed to maintain a favorable bisphosphonate response is \u226533 ng\/ml. Osteoporos Int 23:2479\u20132487. https:\/\/doi.org\/10.1007\/s00198-011-1868-7","journal-title":"Osteoporos Int"},{"key":"6627_CR40","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.maturitas.2014.12.018","volume":"80","author":"M Brincat","year":"2015","unstructured":"Brincat M, Gambin J, Brincat M, Calleja-Agius J (2015) The role of vitamin D in osteoporosis. Maturitas 80:329\u2013332. https:\/\/doi.org\/10.1016\/j.maturitas.2014.12.018","journal-title":"Maturitas"},{"key":"6627_CR41","doi-asserted-by":"publisher","first-page":"e00957","DOI":"10.1002\/PRP2.957","volume":"10","author":"D Kleinermans","year":"2022","unstructured":"Kleinermans D, Joyson | Andrew, Wray | Heather, (2022) An open-label randomized study of the relative absorption of gastro-resistant risedronate taken fasted or with food versus immediate-release risedronate. Pharmacol Res Perspect 10:e00957. https:\/\/doi.org\/10.1002\/PRP2.957","journal-title":"Pharmacol Res Perspect"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-022-06627-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-022-06627-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-022-06627-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,14]],"date-time":"2023-04-14T05:03:44Z","timestamp":1681448624000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00198-022-06627-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,6]]},"references-count":41,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["6627"],"URL":"https:\/\/doi.org\/10.1007\/s00198-022-06627-0","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,6]]},"assertion":[{"value":"22 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. Data are de-identified and comply with the Health Insurance Portability and Accountability Act (HIPAA) of 1996. Accordingly, this study did not require approval from an institutional review board or collection of inform consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"JAE had received research support and\/or consultation fees from Amgen, MSD, Lilly, Theramex. BC has conducted occasional work (consultancies, advice, conferences, clinical studies, courses) for Alexion, Amgen, Aptissen, Expanscience, Ferring, Lilly, Kyowa-Kirin, MSD, Novartis, Theramex, UCB, and Viatris. MB is an employee of Theramex. RII and FV are employees of STATLOG, Inc., which have received research funding from Theramex for this study. JH is an employee of H\u00e9roux Consulting, Inc., which has received research funding from STATLOG for this study. FT has received fees for lectures and consultancy or investigator fees from Amgen, Gedeon Richter, Lilly, Hexal, Kyowa Kirin, Hologic, Novartis, Stada, Synexus, Theramex, and UCB.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}